Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79303.070.269%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Phathom Pharmaceuticals Inc

PHATNASDAQ
Trade with Public
Trade with Public
$9.50
0.454.97%
At close: Sep 4, 5:00 PM EST
$9.41
-0.09-0.95%
After Hours: Sep 4, 7:31 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Phathom Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Phathom Pharmaceuticals (PHAT).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

6Buy
1Hold
Consensus RatingBuy# Analysts7Avg. Consensus PT$19Upside to Avg. PT+97.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 17, 2026BarclaysGlen SantangeloPT CutOverweight$18→$14
Jul 31, 2026GuggenheimYatin SunejaPT CutBuy$25→$22
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
Benzinga Newsdesk

PRO
Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $28 to $22.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
Benzinga Newsdesk

This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday

Top Wall Street analysts upgraded PHAT and PWR, while AGX was upgraded to Overweight with a $550 price target. Check out analysts' views on these stocks.
Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved